Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 6 years
- Director since
- 2023
6 years of board service in total across 2 boards, counting each seat separately. Longest: Bristol-Myers Squibb Company, 3 years.
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 17, 2026 | Guardant Health Inc. | Option exercise | +232 | — | — |
| Sep 17, 2026 | Guardant Health Inc. | Option exercise | +232 | — | — |
| Aug 17, 2026 | Guardant Health Inc. | Option exercise | +232 | — | — |
| Aug 5, 2026 | Guardant Health Inc. | Option exercise | +950 | $32.55 | $30,923 |
| Aug 5, 2026 | Guardant Health Inc. | Open-market sale | −950 | $163.95 | $155,753 |
| Aug 5, 2026 | Guardant Health Inc. | Open-market sale | −750 | $164.61 | $123,458 |
| Jul 17, 2026 | Guardant Health Inc. | Option exercise | +232 | — | — |
| Jun 17, 2026 | Guardant Health Inc. | Option exercise | +232 | — | — |
| Jun 17, 2026 | Guardant Health Inc. | Option exercise | +4,203 | — | — |
| May 28, 2026 | Guardant Health Inc. | Open-market sale | −1,000 | $130.06 | $130,060 |
| May 20, 2026 | Guardant Health Inc. | Option exercise | +1,000 | $32.55 | $32,550 |
| May 20, 2026 | Guardant Health Inc. | Open-market sale | −1,000 | $107.10 | $107,100 |
| May 20, 2026 | Guardant Health Inc. | Open-market sale | −250 | $107.07 | $26,768 |
| May 17, 2026 | Guardant Health Inc. | Option exercise | +232 | — | — |
| Apr 17, 2026 | Guardant Health Inc. | Option exercise | +232 | — | — |
Questions about Medina Manuel Hidalgo
What boards is Medina Manuel Hidalgo on?
Medina Manuel Hidalgo sits on the boards of Bristol-Myers Squibb Company and Guardant Health Inc.
How long has Medina Manuel Hidalgo served on boards?
Our records show at least 6 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.